Lund, Sweden — 12 June 2018 — Camurus AB (Nasdaq STO, CAMX) and Medison Pharma Ltd. announced today an exclusive agreement to commercialize CAM2038 weekly and monthly buprenorphine depot injections in Israel. CAM2038 is being developed for the treatment of adults with moderate to severe opioid dependence, representing a huge global healthcare problem. Under terms of the agreement, Medison will have the exclusive right to commercialize CAM2038 in all indications, including opioid dependence and chronic pain, in Israel. Medison will also be responsible for obtaining regulatory approval for CAM2038 in the territory.
“The agreement with Medison marks an important step in expanding our global partnership network for CAM2038,” said Fredrik Tiberg, President and CEO of Camurus. “Medison has a strong commercial organization in Israel with a proven track record in successfully marketing specialty products, which can give opioid dependent patients in Israel access to a new and effective treatment option.”
“We are very proud to partner with Camurus for CAM2038 in Israel,” said Meir Jakobsohn, Founder and CEO, Medison Pharma. “CAM2038 strengthens our psychiatry and CNS portfolio, fulfilling Medison’s vision to provide innovative treatments to patients in Israel”. “Increasing use of prescription opioids in Israel and the potential of addiction and abuse requires more effective and safer treatments,” said Dr. Matan Ofir, CNS Lead at Medison Ventures. “CAM2038 is a potential game-changer in opioid dependence treatments, providing rapid onset and flexible dosing, improving treatment adherence, quality of life and patient satisfaction”
CAM2038 investigational products are currently under review for market approvals by the European Medicines Agency, the Australian Therapeutic Goods Administration, and the US Food and Drug Administration.
CAM2038 are investigational weekly and monthly buprenorphine injection depots in late-stage clinical development for the treatment of opioid dependence, as a part of a comprehensive treatment plan to include counseling and psychosocial support. The products are designed for flexible dosing, allowing for individualized treatment, in accordance with clinical best practice guidelines, from initiation Day 1 to long-term maintenance therapy. CAM2038 is intended as a stand-alone treatment, obviating the need for additional transmucosal buprenorphine prescriptions. Administration by healthcare professionals increases medication adherence, while minimizing risks of diversion, misuse, and accidental exposure to children, teenagers and pets. CAM2038 has been successfully evaluated in a comprehensive clinical program comprising five Phase 1 and 2 clinical studies, as well as Phase 3 pivotal efficacy and long-term safety studies including both new to treatment patients as well as patients switched from sublingual buprenorphine products.
CAM2038 depots are presented ready for use in prefilled syringes for weekly or monthly administration by a healthcare professional as small dose volume (about 0.6 mL) subcutaneous injection though a thin, 23-gauge needle. CAM2038 is developed for room temperature storage, avoiding the need for cold chain distribution and refrigerator storage. No mixing steps or room temperature conditioning is required prior to administration.
CAM2038 is also being developed for treatment of chronic pain.
Medison, Israel’s leading innovative pharmaceutical partner, is an exclusive Israeli partner for global healthcare companies such as Amgen®, Biogen®, Ipsen®, Vertex® and more. Backed by three generations of experience in the healthcare industry since 1937, Medison has built and maintained long-standing relations with HMOs, local medical centers and physicians. Medison is uniquely qualified to provide the complete spectrum of integrated services for international companies looking to enter or expand their presence in the Israeli market. Medison runs Medison Ventures, a corporate arm with a dedicated research team boasting deep scientific and commercial backgrounds. Medison Ventures operates a scouting program to cater its partners, and is an active investor in life science projects around drug development and digital health.
Camurus is a Swedish research-based pharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the proprietary FluidCrystal® drug delivery technologies and an extensive R&D expertise. Camurus’ clinical pipeline includes products for treatment of cancer, endocrine diseases, pain and addiction, developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker “CAMX”. For more information, visit www.camurus.com.
For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92
Fredrik Joabsson, VP Business Development
Tel. +46 (0)70 776 17 37
The information was submitted for publication at 08.00 am CET on 12 June 2018.